{
    "id": "26873674",
    "text": "FV-100, also known as Cf1743, is an orally available nucleoside analogue drug with antiviral activity. It may be effective against shingles.Tyring SK, Lee P, Hill GT Jr, Silverfield JC, Moore AY, Matkovits T, Sullivan-Bolyai J. FV-100 versus valacyclovir for the prevention of post-herpetic neuralgia and the treatment of acute herpes zoster-associated pain: A randomized-controlled trial. J Med Virol. 2017 Jul;89(7):1255-1264. It was discovered in 1999 in the laboratories of Prof Chris McGuigan, Welsh School of Pharmacy and Prof. Jan Balzarini, Rega Institute, Leuven, Belgium. Shows structure of FV100. ==Clinical trials== FV-100 was tested against valaciclovir in a phase II trial in patients with herpes zoster. The trial was sponsored by Bristol-Myers Squibb. The drug is currently being developed by ContraVir Pharmaceuticals, Inc., Edison, New Jersey. It has reached Phase III clinical trials.De Clercq E, Li G. Approved Antiviral Drugs over the Past 50 Years. Clin Microbiol Rev. 2016 Jul;29(3):695-747. ==References== Category:Anti-herpes virus drugs Category:Nucleosides Category:Antivirals Category:Furopyrimidines Category:Tetrahydrofurans ",
    "title": "FV-100"
}